☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Hemophilia A
Genentech Reports New Data of Hemlibra (emicizumab-kxwh) in P-IIIb STASEY Study to Treat Hemophilia A
July 19, 2021
BioMarin Reports Results of Valoctocogene Roxaparvovec in P-III GENEr8-1 Study for Hemophilia A
January 11, 2021
Pfizer and Sangamo's Giroctocogene Fitelparvovec (SB-525) Demonstrate Positive Effect in P-I/II Alta Study for Hemophilia A
June 19, 2020
BioMarin Receives the US FDA's Priority Review Acceptance of Valoctocogene Roxaparvovec's BLA for Patients with Hemophilia A
February 21, 2020
Novo Nordisk Launches Esperoct [antihemophilic factor (recombinant)- glycopegylated-exei] to Treat Hemophilia A in the US
February 12, 2020
Bluebird Bio Signs a Three-Year Research Collaboration with Novo Nordisk to Develop In-Vivo Genome Editing Therapies for Hemophili...
October 9, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.